PMC:4928686 / 1234-2346 JSONTXT

{"project":"2_test","denotations":[{"id":"25788396-13194679-121220450","span":{"begin":89,"end":90},"obj":"13194679"},{"id":"25788396-13194679-121220450","span":{"begin":89,"end":90},"obj":"13194679"},{"id":"25788396-13350368-121220451","span":{"begin":92,"end":93},"obj":"13350368"},{"id":"25788396-13350368-121220451","span":{"begin":92,"end":93},"obj":"13350368"},{"id":"25788396-25440119-121220452","span":{"begin":675,"end":676},"obj":"25440119"},{"id":"25788396-25440119-121220452","span":{"begin":675,"end":676},"obj":"25440119"},{"id":"25788396-21439328-121220453","span":{"begin":851,"end":852},"obj":"21439328"},{"id":"25788396-21439328-121220453","span":{"begin":851,"end":852},"obj":"21439328"},{"id":"25788396-13194679-68933133","span":{"begin":89,"end":90},"obj":"13194679"},{"id":"25788396-13194679-68933133","span":{"begin":89,"end":90},"obj":"13194679"},{"id":"25788396-13350368-68933134","span":{"begin":92,"end":93},"obj":"13350368"},{"id":"25788396-13350368-68933134","span":{"begin":92,"end":93},"obj":"13350368"},{"id":"25788396-25440119-68933135","span":{"begin":675,"end":676},"obj":"25440119"},{"id":"25788396-25440119-68933135","span":{"begin":675,"end":676},"obj":"25440119"},{"id":"25788396-21439328-68933136","span":{"begin":851,"end":852},"obj":"21439328"},{"id":"25788396-21439328-68933136","span":{"begin":851,"end":852},"obj":"21439328"}],"text":"Introduction\nSince its original description and then isolation by Margaret Gladys Smith [1, 2], cytomegalovirus (CMV) has become well recognized as a pathogen in hosts with impaired immunity. This is most noticeable in those with impaired immunity, such as in congenital infection, in whom the immune system is intentionally suppressed, such as in transplantation, and in disease-imposed impairment of immunity, such as in human immunodeficiency virus and acquired immune deficiency syndrome.\nWith advances in monitoring and detection methods, CMV has been recognized to reactivate in numerous settings in individuals that are not chronically immune suppressed (reviewed in [3]). As will be discussed, there are growing data suggesting that such reactivation events could be pathogenic in previously immune-competent patients during critical illness [4]. In the current review, immune competent patients that have CMV reactivation will be referred to as non-immune suppressed, acknowledging that these previously immune competent patients might have transient immune compromise as a consequence of their illness."}